In 2023, there were an estimated 1.03 million cases of chlamydia among women in the United States and around 610,445 cases among men. Furthermore, that year, there were around 378,428 cases of gonorrhea among men and 221,176 cases among women. Despite the dangers of sexually transmitted diseases (STDs) being more commonplace and testing and contraception, for the most part, widely accessible in the United States, rates of chlamydia, gonorrhea, and syphilis, have all risen in recent years. Chlamydia in the United States According to the CDC, chlamydia is the most commonly reported bacterial sexually transmitted infection (STI) in the United States. In 2023, there were around 492 cases of chlamydia per 100,000 population, a substantial increase from a rate of 289 per 100,000 population in the year 2002. Those aged 20 to 24 had the highest rates of chlamydia in the U.S. in 2023. Although chlamydia often has no symptoms, it can cause serious health problems if left untreated, one of the reasons those who are sexually active should be regularly tested for STDs. Once diagnosed, chlamydia can be easily cured with antibiotics. Gonorrhea Rates of gonorrhea in the United States decreased after reaching a peak in the 1980s but began to rise again over the past decade. In 2023, there were 179.5 cases of gonorrhea per 100,000 population in the United States, compared to 98 cases per 100,000 population in the year 2009. While rates of chlamydia in the U.S. tend to be higher among women than men, rates of gonorrhea are higher among men, with those aged 20 to 24 the most affected. Like chlamydia, gonorrhea can be cured with medicine but can cause serious and permanent health problems if left untreated.

In 2023, the highest rates of chlamydia in the U.S. were reported for the Black population, with men having a rate of 974.7 per 100,000 population and women a rate of 1,342.2 per 100,000 population. This statistic shows the rates of reported cases of chlamydia in the United States in 2023, by race/ethnicity and gender.

Rates of syphilis in the United States are higher among men than women. This is true for every race and ethnicity, although the difference varies greatly. For example, among the Black population, there were around 62.3 cases of syphilis among men per 100,000 population in 2023 and only 18.8 cases per 100,000 population among women. On the other hand, rates of syphilis among American Indians/Alaska Natives were similarly high for both men and women with rates of 63.6 and 52.9 per 100,000 population, respectively. What is syphilis? Syphilis is a common and treatable sexually transmitted disease (STD). Anyone who is sexually active can contract syphilis, however men who have sex with only men accounted for slightly more cases than other groups in 2022. There are four stages of syphilis, and each stage has different signs and symptoms. The stages are primary, secondary, latent, and tertiary. Syphilis can be cured with antibiotics. How many people get syphilis each year? In 2022, there were around 207,255 cases of syphilis in the United States. This was the highest number of cases recorded since the 1950s. In comparison, in the year 2000, there were only around 31,618 cases. Like chlamydia and gonorrhea, rates of syphilis in the United States have increased over the past couple decades reaching 62 per 100,000 population in 2022. However, this rate is still far below the rate of 146 cases per 100,000 population recorded in 1950. Rates of syphilis in the U.S. are highest among people in their twenties and early thirties.

In 2023, Alaska had the highest rate of gonorrhea in the United States with around 311 new cases per 100,000 population. This statistic represents the rate of gonorrhea among adults in the United States as of 2023.

Snapshot img

Sexually Transmitted Diseases Treatment Market Size 2024-2028

The sexually transmitted diseases (STD) treatment market size is forecast to increase by USD 14.3 billion at a CAGR of 4.5% between 2023 and 2028.

The market is experiencing significant growth due to several key factors. The increasing prevalence of STDs worldwide is a major driver for market expansion. According to the World Health Organization, there were an estimated 376 million new cases of curable STDs in 2012. According to the World Health Organization, approximately one million new STD infections occur daily worldwide. Bacterial STDs, such as Chlamydia and Gonorrhea, can be effectively treated with antibiotics. Advances in rapid diagnosis techniques are also contributing to market growth, allowing for earlier detection and treatment of STDs. However, limited healthcare services in developing regions pose a challenge to effective STD treatment, particularly in populations that are most at risk. Despite these challenges, the market is expected to continue growing as efforts to increase awareness and access to healthcare services persist. The market analysis report provides a comprehensive examination of these trends and the factors shaping the future of the STD treatment market.

What will be the Size of the STD Treatment Market During the Forecast Period?

Request Free Sample

The market encompasses a range of contagious and serious conditions that affect the reproductive organs and require medical intervention. Bacterial STDs, such as gonorrhea and syphilis, can be treated with antibiotics, while viral STDs, including HIV/AIDS, hepatitis B, and genital warts, often require antiretroviral drugs or suppressive therapy. Symptoms of these infections can vary from nonexistent to severe, making early diagnosis and treatment crucial to prevent permanent damage and potential complications. The market for STD treatments and infectious disease diagnostics continues to evolve, with ongoing research and development efforts aimed at creating more effective medications and vaccines.
Additionally, antibiotic-resistant strains of gonorrhea and syphilis pose a challenge, necessitating the exploration of alternative treatment options. Antiviral medication and surgical interventions, such as freezing or removal of genital warts, also play a role in managing these conditions. Outbreaks of STDs can lead to increased demand for treatments and heightened awareness of the importance of safe sexual practices. The ongoing global fight against HIV/AIDS and efforts to improve access to STD testing and treatment for underserved populations remain key priorities in the market.
The sexually transmitted diseases (STD) treatment market is evolving with advancements in both pharmaceutical and diagnostic technologies. Antiviral STD drugs and antibiotic STD treatments are essential for managing infections like gonorrhea, chlamydia, and syphilis, with updated syphilis treatment guidelines ensuring more effective care. HIV antiretroviral therapy remains critical for managing HIV, while herpes treatment advancements continue to improve patient outcomes. The HPV vaccine market is also expanding, providing a preventive measure for HPV-related cancers. Bacterial vaginosis drugs and trichomoniasis medication address common infections, while STD rapid test kits and STI prevention therapies are enhancing early detection and prevention efforts. Emerging STD drug research and telemedicine for STD treatment are further improving accessibility and patient care in public health STD initiatives.

How is this Sexually Transmitted Diseases Treatment Industry segmented and which is the largest segment?

The sexually transmitted diseases (STD) treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Viral infections
  Bacterial infections
  Others


Geography

  North America

    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Type Insights

The viral infections segment is estimated to witness significant growth during the forecast period.

The market is driven by the rise in viral STD infections, such as human papillomavirus (HPV), herpes simplex virus (HSV), hepatitis B virus (HBV), and HIV. According to the Centers for Disease Control and Prevention (CDC), genital HPV infection is the most common STD in the US, affecting approximately 45% of adults aged 18-59 years during 2021-2022. HPV can lead to health complications, including cervical cancer and genital warts. Other viral STDs, such as genital herpes and hepatitis B, can also cause significant health issues. Antiviral medications and suppressive therapy are common treatments for viral STDs, while vaccines are

The highest rate of syphilis within the period from 1950 to 2023 was reported in 1950 with 146 cases per every 100,000 population in the United States. This statistic shows the timeline of rates of reported cases of syphilis in the United States for selected years between 1950 to 2023.

In 2023, Louisiana had the highest rate of chlamydia in the United States with around 792 new cases per 100,000 population. This statistic represents the rate of chlamydia among adults in the United States as of 2023.

Sexually Transmitted Disease (STD) Testing Market Outlook

The global market size for Sexually Transmitted Disease (STD) Testing was valued at approximately USD 14.3 billion in 2023 and is projected to reach around USD 24.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.2%. A significant growth factor for this market is the rising prevalence of sexually transmitted diseases (STDs) worldwide, which necessitates effective and timely diagnostic measures to control the spread and complications associated with these infections.

The increasing awareness about sexual health and the importance of early detection of STDs is one of the primary growth drivers of the STD testing market. Government and non-government organizations are actively involved in campaigns and programs aimed at increasing awareness and reducing the stigma associated with STDs, encouraging more individuals to get tested. Additionally, advancements in diagnostic technologies have made STD testing more accessible, quicker, and accurate, further propelling the market growth. Innovations such as rapid tests and home-based testing kits have significantly contributed to the ease and convenience of getting tested, thereby boosting market demand.

Another crucial factor contributing to the growth of the STD testing market is the rise in high-risk behaviors such as unprotected sex, multiple sexual partners, and drug use. These behaviors have led to an increase in STD incidences, driving the need for comprehensive testing solutions. Moreover, the global travel and migration patterns have also played a role in the spread of STDs, further emphasizing the need for robust STD testing infrastructure. Additionally, the integration of STD testing services with routine health check-ups in healthcare settings has normalized the process and increased the testing uptake among individuals.

The STD testing market is also benefiting from the substantial investments in healthcare infrastructure by both public and private sectors. Governments across various regions are allocating significant budgets to improve diagnostic facilities and make STD testing more widely available. The involvement of private players in offering specialized STD testing services has also created a competitive market, leading to better service quality and availability. Furthermore, the implementation of favorable reimbursement policies for STD testing in several countries is expected to drive market growth, as it reduces the financial burden on individuals seeking testing services.

Regionally, North America holds a significant share in the STD testing market due to the high prevalence of STDs, advanced healthcare infrastructure, and supportive governmental policies. Europe also shows substantial market growth potential, driven by the rising awareness and implementation of comprehensive sexual health programs. The Asia Pacific region is expected to witness the fastest growth during the forecast period, attributed to the large population base, increasing healthcare investments, and growing awareness about STDs. Latin America and the Middle East & Africa are also anticipated to contribute to the market growth, although at a relatively slower pace due to varying levels of healthcare infrastructure and awareness.

Test Type Analysis

The test type segment of the STD testing market includes various specific tests such as Chlamydia, Gonorrhea, Syphilis, Herpes Simplex Virus, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), and others. Each of these diseases requires different diagnostic techniques and has varying levels of prevalence, impacting the market dynamics for each test type. Chlamydia testing is one of the largest segments due to the high incidence rate of the infection globally. Chlamydia is often asymptomatic, which necessitates regular screening, especially among sexually active individuals, driving the demand for Chlamydia testing kits and services.

Chlamydia Infection Test is a critical component of the STD testing market, given the high prevalence and often asymptomatic nature of the infection. Regular screening for Chlamydia is recommended for sexually active individuals, especially young women, to prevent long-term health complications such as infertility and pelvic inflammatory disease. The availability of non-invasive testing methods, such as urine tests and swabs, has increased the accessibility and convenience of Chlamydia testing. Public health initiatives that promote rout

Sexually Transmitted Disease (STD) Drug Market Outlook

The global sexually transmitted disease (STD) drug market size was valued at approximately USD 18.2 billion in 2023 and is expected to reach around USD 29.4 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period. The rising prevalence of STDs, increasing awareness about sexual health, and advancements in diagnostic technologies are significant factors driving this market's growth. Enhanced access to healthcare services, coupled with robust government initiatives, is also propelling market expansion.

One of the primary growth drivers of the STD drug market is the rising incidence of sexually transmitted infections (STIs) globally. With changing sexual behaviors and increasing urbanization, the incidence rates of diseases like Chlamydia, Gonorrhea, and Syphilis have seen a significant uptick. This growing burden of diseases necessitates the development and distribution of effective medications, thereby fueling market growth. Additionally, technological advancements in diagnostic tests have made it easier to identify these diseases early, leading to timely treatment and better patient outcomes.

Public health initiatives and awareness campaigns have also played a crucial role in the market's expansion. Governments and non-governmental organizations are increasingly focusing on sexual health education to reduce STDs' prevalence. Such initiatives not only promote preventive measures but also encourage individuals to seek medical help when needed, thereby boosting the demand for STD drugs. Moreover, funding for research and development in this area has surged, leading to the introduction of new and more effective treatments.

Another significant factor contributing to the market's growth is the improvement in healthcare infrastructure, especially in developing regions. Better healthcare facilities and increased access to medications have made it easier for people to get diagnosed and treated for STDs. Additionally, telemedicine and online pharmacies have emerged as convenient options for patients, further increasing drug accessibility. All these factors collectively enhance the market's growth trajectory.

Regionally, North America holds the largest share of the STD drug market, primarily due to high awareness levels, advanced healthcare systems, and robust R&D activities. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by increasing healthcare expenditure, rising awareness, and a higher incidence rate of STDs. Latin America, Europe, and the Middle East & Africa are also contributing significantly to the market, each with unique growth factors and challenges.

Drug Class Analysis

The STD drug market is segmented into various drug classes, including antibiotics, antivirals, vaccines, and others. Antibiotics have traditionally dominated the market due to their effectiveness in treating bacterial infections such as Chlamydia and Gonorrhea. These drugs are widely prescribed and have been the mainstay in STD treatment protocols. The increasing incidence of antibiotic-resistant strains, however, is driving the need for novel antibiotics and combination therapies.

Antivirals are another vital segment, particularly for viral infections like Herpes Simplex Virus (HSV) and Human Immunodeficiency Virus (HIV). The development of highly effective antiviral medications has significantly improved the quality of life for patients suffering from these infections. Antiviral drugs such as acyclovir and valacyclovir are commonly used to manage symptoms and reduce the frequency of outbreaks, thereby making them indispensable in STD treatment.

Vaccines represent a growing segment in the STD drug market, particularly for Human Papillomavirus (HPV) and Hepatitis B. The introduction of vaccines like Gardasil and Cervarix has proven effective in preventing certain types of HPV, which are linked to cervical cancer. The acceptance and widespread use of these vaccines are expected to grow, driven by strong advocacy from public health organizations and increasing awareness about their benefits.

The "Others" category includes a range of medications and therapies that do not fit into the traditional antibiotic or antiviral classifications. This segment includes emerging treatment modalities such as immunotherapies and novel drug delivery systems. These innovative approaches are gaining traction as they offer new ways to m

According to Cognitive Market Research, the global HIV Diagnostics market size is USD 4158.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 10.90% from 2024 to 2031. North America held the major market share for more than 40% of the global revenue with a market size of USD 1663.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1247.46 million. Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 956.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031. Latin America had a market share of more than 5% of the global revenue with a market size of USD 207.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031. Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 83.16 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031. Consumables held the highest HIV Diagnostics market revenue share in 2024. Market Dynamics of HIV Diagnostics Market Key Drivers for HIV Diagnostics Market Increasing Prevalence of Sexually Transmitted Disease to Increase the Demand Globally Throughout the many decades of the HIV pandemic, the number of infected individuals is continually rising. The socioeconomic variables driving this continuous increase also suggest that preventative measures have not been successful. Even though many of these infections are preventable, there are an estimated 20 million new cases of STDs in the US each year, and the rate is still rising. Moreover, there are over 1.2 million HIV-positive individuals residing in the United States. Attempts to encourage testing and screening for sexually transmitted infections can ascertain an individual's likelihood of acquiring one and help those who already have one receive treatment, so enhancing their health and lowering the danger of HIV spreading to others. Approximately 38.4 million people worldwide were HIV positive in 2021. Among these, women and girls made up nearly 54%. Rising Initiatives by Global Agencies to Propel Market Growth HIV is among the world's most important public health concerns. As a result, there is a global commitment to stopping new HIV infections and giving everyone on the planet access to HIV therapy. WHO recommends testing for HIV to anyone who might be at risk. The World Bank was a leader in global financing for HIV/AIDS in the early phases of the pandemic and has contributed US$4.6 billion to programs related to the illness since 1989. Because of assistance from the Bank—more precisely, through the International Development Association—for 1,500 counseling and testing centers, about 7 million people have had HIV tests. Restraint Factor for the HIV Diagnostics Market Lack of Healthcare Infrastructure and Awareness to Limit the Sales A proper infrastructure for healthcare delivery is lacking in many areas, especially in poor nations, which makes it difficult to provide diagnostic services. This covers concerns with the supply chain, inadequate laboratory facilities, and skilled staff. It might be particularly difficult to access diagnostic services in rural and isolated places due to a lack of healthcare facilities and inadequate transportation infrastructure. Furthermore, HIV diagnosis rates are lower in the developing Asia-Pacific, Middle East, and African regions. These areas require a sufficient number of diagnostic facilities. Additionally, the diagnosis process needs to be explained to the majority of patients, which restricts market growth in these areas. Impact of Covid-19 on the HIV Diagnostics Market The COVID-19 pandemic has had a significant impact on the HIV diagnostics market, both in terms of challenges and opportunities. There was a decrease in HIV testing and diagnostic services during the pandemic as a result of the extensive healthcare resources being redirected to handle COVID-19. Some facilities were converted to provide COVID-19 treatment, and clinics and labs had a staffing crisis. Reduced HIV testing rates were the outcome of routine and community-based HIV testing programs being frequently halted to stop the spread of COVID-19. The adoption of telemedicine and remote healthcare services was expedited by the epidem...

In 2021, around 30.5 cases of chlamydia were reported on average per medical institution in Japan, representing the highest point in the last decade. That year, the number of herpes genitalis saw a slight decrease to 9.14 reported cases on average.

The size of the Contraceptive Industry in U.S. market was valued at USD 5.12 Million in 2023 and is projected to reach USD 7.66 Million by 2032, with an expected CAGR of 5.93% during the forecast period.The US contraceptive industry has been transformed for decades due to a response to changes in healthcare, changing social norms, and growing knowledge about family planning and sexual health. The market is vast and may encompass items such as: hormonal contraceptives such as pills, patches, and injections; barrier methods in the form of condoms and diaphragms; intrauterine devices (IUDs); and emergency contraception. The prescription-based products, especially oral contraceptives and intrauterine devices, make the largest segment of the market. Due to the wide availability of over-the-counter varieties, such as condoms and emergency contraceptives, they also fall under this category.Among the factors that contributed to the rapid growth of the contraceptive market in the U.S. include government programs about reproductive health, increased access to care through Affordable Care Act provisions, and the rising knowledge base about STIs. Long-acting reversible contraceptives, including IUDs and implants, also have high rates of success and are easy to apply and remove, making them in strong demand.Cultural and religious opposing views and probable high costs of some products will be constraining the growth of the market. Increased legal and political debate surrounding the reproduction rights, like access to contraception and abortion services, would further complicate the direction of the future of the industry Key drivers for this market are: Rise in Government Initiatives and Increasing Awareness about Sexually Transmitted Diseases (STDs), Rising Rate of Unintended Pregnancies. Potential restraints include: Side Effects Associated with the Use of Contraceptive Devices. Notable trends are: Condoms are Expected to Dominate the USA Contraceptive Devices Market.

IMPORTANCE: In the United States, the prevalence rates of Human Immunodeficiency Virus (HIV) and sexually transmitted infections (STIs) are higher among individuals in community supervision programs (CSPs) than in the general population. However, to date, no couple-based HIV or STI prevention interventions have been implemented for the large number of men in CSPs. OBJECTIVE: To determine the effectiveness of a 5-session couple-based prevention intervention, compared with a 1-session counseling, testing, and referral (CTR) program, in reducing HIV and STIs as well as condomless intercourse among men in CSPs and their female sexual partners. DESIGN, SETTING, AND PARTICIPANTS: A randomized controlled trial was conducted from July 11, 2013 (first recruitment), through May 17, 2016 (last randomization). Participants were drug-involved men mandated to a CSP and their female sexual partners (n = 230 couples or 460 individuals). Participants were recruited from various CSP sites in New York, New York, and randomized into either the PACT (Protect and Connect) intervention condition or the HIV CTR control condition (n = 115 couples or 230 individuals in each arm). Analysis of behavioral outcomes used an intent-to-treat approach. Statistical analyses were conducted from November 1, 2017, through June 1, 2018. MAIN OUTCOMES AND MEASURES: Self-reported data on sexual behaviors in the past 90 days were used to assess behavioral outcomes at all time points. Biomarkers were collected at baseline and 12 months, and behavioral outcomes were collected at baseline and 3, 6, and 12 months. RESULTS: A total of 230 couples (460 individuals) were included. The mean (SD) age of participants was 35.0 (12.8) years, and most participants (341[74.1%]) self-identified as black or African American race/ethnicity. Of the 18 new cases of STIs identified at the 12-month assessment, 10 came from the PACT arm and 8 from the HIV CTR control arm. Compared with the control participants, PACT participants had 33% fewer acts of condomless vaginal and/or anal intercourse with their main partner (incidence rate ratio [IRR], 0.67; 95% CI, 0.45-0.99; p = .04), 70% fewer acts with other partners (IRR, 0.30; 95% CI, 0.12-0.74, p = .009), and 40% fewer acts with all sexual partners (IRR, 0.60; 95% CI, 0.42-0.85; p = .005) over the entire follow-up period. In addition, PACT participants were less likely to report being under the influence of drugs or alcohol the last time they had vaginal and/or anal intercourse with their study partners (odds ratio, 0.55; 95% CI, 0.31-0.96; p = .04) and had 26% fewer sex partners in the past 90 days (IRR, 0.74; 95% CI, 0.61-0.88; p = .001). At 12 months, HIV and STI incidence did not differ significantly between the 2 arms. CONCLUSIONS AND RELEVANCE: The PACT intervention appeared to reduce risky sexual behaviors, such as condomless intercourse; this finding suggests that a couple-based HIV and STI prevention intervention program may curb the burgeoning HIV epidemic in CSPs. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01690494

Snapshot img

Socially Stigmatized Diseases Market Size 2024-2028

The socially stigmatized diseases market size is forecast to increase by USD 343.5 billion, at a CAGR of 8.2% between 2023 and 2028.

The market is experiencing significant growth due to several key factors. One of the primary drivers is the high prevalence of diseases such as HIV and AIDS, which necessitates the development of effective treatments and delivery routes. Another trend is the increasing availability of medication for these diseases online, making it more accessible to those who may face social stigma or geographical barriers. However, there are also challenges that must be addressed, including bottlenecks in the supply chain and the persistent social stigma surrounding these diseases, which can hinder access to healthcare and treatment. To address these challenges, it is essential to focus on improving delivery routes and addressing the root causes of social stigma. By doing so, we can ensure that those in need have access to the care and treatment they require, ultimately leading to better health outcomes and a reduced burden on healthcare systems.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market encompasses a range of health conditions that carry a significant social stigma, often leading to discrimination and marginalization. Effective data management and real-time analytics are crucial for understanding the dynamics of these diseases, improving public health interventions, and mitigating their societal impact. Data management in the market faces unique challenges. The lack of standardization in data collection, storage, and sharing across various industries and sectors hampers comprehensive disease surveillance and response efforts. Moreover, the sensitive nature of medical information associated with these diseases necessitates strong data security measures. Graph databases and property graph models offer promising solutions to address these challenges. Graph databases enable efficient handling of complex relationships between vertices (nodes) and edges (connections) in data. Labels can be assigned to vertices to represent different disease entities, while indexes facilitate rapid data retrieval.
In the market, long tasks and stored procedures are essential for processing large volumes of data in real-time. Real-time analytics enables logistics professionals in the finance and logistics industries to optimize routes, manage warehouses, and ensure efficient disease surveillance. The finance industry can leverage data modeling and visualization tools to identify patterns and trends in financial transactions related to socially stigmatized diseases. This information can inform investment strategies and risk assessments. In the logistics industry, real-time analytics can optimize supply chain operations and improve response times to disease outbreaks. Data centers and cloud regions play a vital role market by providing secure, scalable, and cost-effective storage solutions. Business processes can be automated using programming ease and visualization tools, enabling more efficient data analysis and decision-making.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Disease Type

  STIs
  Mental health disorders
  Cancer
  Others


Therapy

  Medications
  Therapy and counseling
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Disease Type Insights

The STIs segment is estimated to witness significant growth during the forecast period.

Sexually transmitted infections (STIs), also known as sexually transmitted diseases (STDs), are a significant sector within the global market for socially stigmatized diseases. These infections are contracted through sexual contact, affecting various parts of the body including the mouth, anus, vagina, and penis. STIs encompass a range of conditions, each presenting unique symptoms and health consequences. Common symptoms include discomfort such as burning sensations and itching in the genital area, as well as discharge. In India, as of 2023, the prevalence of STIs is substantial, with around 6% of the adult population reportedly affected by one or more STIs or reproductive tract infections (RTIs). This equates to approximately 30 to 35 million cases annually, underscoring the considerable public health challenge posed by these infections.

Get a glance at the market report of share of various segments Request Free Sample

The STIs segment was valued at USD 254.10 billion in 2018 and

The global syphilis testing market is estimated to reach USD 1.03 billion by 2033, growing at a CAGR of 3.46% from 2025 to 2033. Increasing prevalence of sexually transmitted infections (STIs) and government initiatives for STI screening programs are expected to drive market growth. Technological advancements in syphilis testing methods, such as automated syphilis testing systems and point-of-care syphilis testing devices, are also contributing to market growth. The market is segmented by sample type (blood, serum, plasma, cerebrospinal fluid), technology (enzyme immunoassay (EIA), chemiluminescence immunoassay (CLIA), rapid plasma reagin (RPR), test Treponema Pallidum particle agglutination (TPPA), test fluorescent treponemal antibody absorption (FTA-ABS)), product type (automated syphilis testing systems, manual syphilis testing kits, point-of-care syphilis testing devices), and region (North America, South America, Europe, Middle East & Africa, Asia Pacific). North America is expected to hold the largest market share due to the high prevalence of STIs and well-established healthcare infrastructure. Asia Pacific is expected to witness the highest growth rate due to the increasing awareness of STIs and government initiatives for STI screening programs. Key drivers for this market are: Rising prevalence of sexually transmitted infections Technological advancements in testing methods Increasing awareness about syphilis prevention and treatment Expanding access to healthcare services Growing demand for point-of-care diagnostics. Potential restraints include: Increasing prevalence of technological advancements, rising awareness of government initiatives; favorable reimbursement policies.

According to Cognitive Market Research, the global Chlamydia Infection Diagnostic Therapeutic Market size will be USD 1624.8 million in 2025. It is expected to expand at a compound annual growth rate (CAGR) of 8.00% from 2025 to 2033.

North America held the major market share for more than 37% of the global revenue with a market size of USD 601.18 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2033.
Europe accounted for a market share of over 29% of the global revenue, with a market size of USD 471.19 million.
APAC held a market share of around 24% of the global revenue with a market size of USD 389.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2025 to 2033.
South America has a market share of more than 3.8% of the global revenue, with a market size of USD 61.74 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2025 to 2033.
Middle East had a market share of around 4% of the global revenue and was estimated at a market size of USD 64.99 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2033.
Africa had a market share of around 2.2% of the global revenue and was estimated at a market size of USD 35.75 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
Hospitals are the fastest growing segment of the Chlamydia Infection Diagnostic Therapeutic Market industry

Market Dynamics of Chlamydia Infection Diagnostic Therapeutic Market

Key Drivers for Chlamydia Infection Diagnostic Therapeutic Market

Expanding At-Home STI Testing Supported by Regulatory Authorities Is Expected To Boost Market Growth

A major factor driving the market for chlamydia diagnostics is the support from regulatory bodies and the rise of at-home testing options, which government health organizations have strongly promoted. The U.S. Centers for Disease Control and Prevention (CDC) reports that chlamydia continues to be the most reported sexually transmitted infection in the United States, with over 1.6 million cases recorded in 2023. This accounts for nearly half of the total 2.4 million STI cases reported that year. The high prevalence of chlamydia has led government agencies to push for more screening and early detection, especially among high-risk groups like adolescents and young adults, who make up about 48% of chlamydia cases. To support this public health initiative, regulators such as the FDA have expedited approval processes and set clear guidelines for at-home and point-of-care diagnostic tests. This makes testing more accessible and integrates it into national efforts to control STIs. By breaking down traditional barriers—like the stigma associated with clinic visits, logistical challenges, and privacy issues—these government-backed approvals help facilitate earlier diagnoses, faster treatments, and ultimately reduce transmission rates. In March 2025, the U.S. Food and Drug Administration approved the Visby Medical Women’s Sexual Health Test, marking the first over-the-counter, fully at-home PCR test that can diagnose chlamydia, gonorrhea, and trichomoniasis in just 30 minutes, without the need for a prescription. This achievement highlights the government's commitment to making STI testing more accessible, aligning with public health objectives to enhance early detection, diminish stigma, and improve access to care.

https://www.fda.gov/news-events/press-announcements/fda-grants-marketing-authorization-first-home-test-chlamydia-gonorrhea-and-trichomoniasis”/

Government-Supported National Chlamydia Screening Expansion To Boost Market Growth

According to the UK Health Security Agency (UKHSA), England’s National Chlamydia Screening Programme (NCSP) has made great strides in expanding routine testing for sexually active individuals aged 15 to 24, with a particular emphasis on young women. In 2022, the NCSP reported nearly 4.4 million consultations at sexual health services—an 8.2% increase from the previous year. They conducted 2.2 million chlamydia tests, which represents a 13.4% rise in screening efforts. The guidance specifically aims to minimize reproductive health issues by promoting proactive testing in community settings, such as GP clinics and pharmacies, along with rapid treatment, partner notification, and retesting initiatives. This ongoing governme...

T. vaginalis infection (trichomoniasis) is the most common curable sexually transmitted infection (STI) in the U.S. It is associated with increased HIV risk and adverse pregnancy outcomes. Trichomoniasis surveillance data do not exist for either national or local populations. The Monitoring STIs Survey Program (MSSP) collected survey data and specimens which were tested using nucleic acid amplification tests to monitor trichomoniasis and other STIs in 2006–09 among a probability sample of young adults (N = 2,936) in Baltimore, Maryland — an urban area with high rates of reported STIs. The estimated prevalence of trichomoniasis was 7.5% (95% CI 6.3, 9.1) in the overall population and 16.1% (95% CI 13.0, 19.8) among Black women. The overwhelming majority of infected men (98.5%) and women (73.3%) were asymptomatic. Infections were more common in both women (OR = 3.6, 95% CI 1.6, 8.2) and men (OR = 9.0, 95% CI 1.8, 44.3) with concurrent chlamydial infection. Trichomoniasis did not vary significantly by age for either men or women. Women with two or more partners in the past year and women with a history of personal or partner incarceration were more likely to have an infection. Overall, these results suggest that routine T vaginalis screening in populations at elevated risk of infection should be considered.

The global market for Chlamydia infection diagnostics is experiencing robust growth, driven by rising prevalence of Chlamydia trachomatis infections, increased awareness of sexually transmitted infections (STIs), and advancements in diagnostic technologies. The market, currently estimated at $1.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching an estimated market value of approximately $2.7 billion by 2033. Key factors contributing to this growth include the increasing adoption of Nucleic Acid Amplification Tests (NAATs), which offer higher sensitivity and specificity compared to traditional methods. Furthermore, the expansion of screening programs, particularly in high-risk populations, is fueling demand for accurate and reliable diagnostic tools. The market is segmented by application (hospitals, specialty clinics, diagnostic centers) and test type (NAATs, direct fluorescent tests, others), with NAATs dominating due to their superior performance. Geographically, North America currently holds the largest market share, followed by Europe, driven by advanced healthcare infrastructure and high diagnostic rates. However, Asia-Pacific is expected to witness significant growth in the coming years due to rising healthcare expenditure and increasing awareness about STIs in developing economies. The market faces certain restraints, including the high cost of advanced diagnostic technologies and limited access to healthcare in underserved regions. Despite these challenges, the market is poised for continued expansion. Major players like BD Medical, Bio-Rad Laboratories, Abbott Laboratories, and Roche are actively investing in research and development to improve diagnostic accuracy, reduce costs, and introduce innovative testing methodologies. The development of point-of-care testing (POCT) devices, offering rapid and convenient diagnosis, is another key trend driving market growth. The integration of digital technologies, such as telemedicine and electronic health records, is also streamlining diagnostic processes and improving patient outcomes. Future growth will depend on continued investment in healthcare infrastructure, increased public health awareness campaigns, and the development of more affordable and accessible diagnostic solutions, especially in low- and middle-income countries.

PurposeHerpes simplex virus 2 (HSV-2) causes genital herpes, one of the most common sexually transmitted infections (STIs) in the U.S. HSV-1, commonly associated with cold sores, is increasing as a cause of genital herpes. Abstinence-only sexual health classes, commonly taught in Virginia, generate young adults who are under-educated in sexual health, increasing STI risks. College students in southwest Virginia were surveyed to assess comprehensiveness of high school health education regarding HSV-1 and HSV-2 and to identify students’ preferred methods for STI education.MethodsTo obtain data on knowledge of HSV, comprehensiveness of sexual health education in high school, and preferred learning methods, 237 college students participated in an online questionnaire and 28 students were interviewed using structured interviews.ResultsQuestionnaire and interview data indicated that Family Life Education classes need to include more comprehensive information on prevention, viral transmission, and differences between HSV-1 and HSV-2. The majority of total respondents (both the questionnaire and interview) (65%) reported non-comprehensive high school sexual health education. The majority of interview (79%) and questionnaire (55%) respondents wished they had learned more about herpes and other STIs in high school. Education preferences of both interviewed and surveyed respondents included interactive internet programs or games, more realistic lectures, and learning about STIs later in high school when students reported greater sexual activity.ConclusionOur results indicate that more comprehensive sexual health education is needed and wanted by students in southwest Virginia. More relevant educational programs should be implemented for VA high school students utilizing technology and interactive methods to improve student engagement in sexual health education.Implications and contributionThese studies provide information on knowledge of herpes simplex viruses among college students, comprehensiveness of sexual health education received in high schools, and preferred methods to learn about HSV and other STIs. These studies inform the facilitation of improved health education practices and programs for high school and college students.

BackgroundSexually transmitted infections (STIs) are some of the most common communicable conditions and exert impact on the health and lives of many hundreds of millions of people across the world every year. Screening high-risk populations and conducting comprehensive detection tests would lead to a significant improvement in preventing the transmission of STIs and help us to provide rapid treatment to those affected. Here, we successfully established and validated a novel high-throughput multiplex gene detection system (HMGS) for the simultaneous and semiquantitative detection of six important curable sexually transmitted pathogens in a single reaction from secretions samples.MethodFluorescently labeled primers were designed to target specific conserved and single-copy gene fragments of Ureaplasma urealyticum (U. urealyticum), Mycoplasma hominis (M. hominis), Chlamydia trachomatis (C. trachomatis), Neisseria gonorrhoeae (N. gonorrhoeae), Trichomonas vaginalis (T. vaginalis), and Treponema pallidum (T. pallidum). The specificity and sensitivity of the STI-HMGS was validated and optimized using plasmids and quantitative genomic DNA. Next, we validated the performances of the STI-HMGS for clinical application by testing samples of clinical secretions collected from patients who visited the gynecology and urology outpatient clinics of our reproductive medicine center. Results derived from the STI-HMGS were then compared with three approved commercialized kits that used to detect U. urealyticum, C. trachomatis and N. gonorrhoeae, respectively, followed by further validation with Sanger sequencing for all pathogens. Finally, a comprehensive analysis of epidemiology was performed among different subgroups to investigate the association between infection rates and clinically-relevant information.ResultsThe sensitivity of STI-HMGS for six target genes was 10 copies/µL. Data derived from the detection of 381 clinical secretions demonstrated that the STI-HMGS exhibited high concordance rate compared with approved commercialized kits and almost 100% sensitivity and specificity for the detection of six sexually transmitted pathogens when validated by Sanger sequencing. Semi-quantitative analysis found that STIs caused by N. gonorrhoeae had a significantly higher (P